NASDAQ:CTIC - CTI BioPharma News Headlines

Sign in or create an account to add this stock to your watchlist.
$0.93 -0.02 (-2.11 %)
(As of 02/21/2019 04:32 AM ET)
Previous Close$0.95
Today's Range$0.93 - $0.96
52-Week Range$0.60 - $5.36
Volume160,600 shs
Average Volume372,879 shs
Market Capitalization$53.93 million
P/E Ratio-0.75
Dividend YieldN/A
Beta1.75

Headlines

CTI BioPharma (NASDAQ CTIC) News Headlines

Source:
DateHeadline
CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27CTI BioPharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference Wednesday, Feb. 27
finance.yahoo.com - February 20 at 9:44 AM
CTI BioPharma Corp (CTIC) Given Average Recommendation of "Buy" by BrokeragesCTI BioPharma Corp (CTIC) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 20 at 5:34 AM
CTI BioPharma collects $10M payment for former chemotherapy drugCTI BioPharma collects $10M payment for former chemotherapy drug
finance.yahoo.com - February 13 at 9:38 AM
CTI Trumpets Teva Milestone PaymentCTI Trumpets Teva Milestone Payment
www.baystreet.ca - February 11 at 10:53 AM
CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®CTI BioPharma Receives $10 Million Milestone Payment for TRISENOX®
finance.yahoo.com - February 11 at 10:52 AM
Ex-CTI BioPharma CEO seeks startup funds as yacht lawsuit dismissedEx-CTI BioPharma CEO seeks startup funds as yacht lawsuit dismissed
finance.yahoo.com - February 9 at 9:14 AM
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update - PRNewswireCTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update - PRNewswire
www.prnewswire.com - February 1 at 5:39 PM
CTI Bio down 8% premarket on withdrawal of pacritinib application in EuropeCTI Bio down 8% premarket on withdrawal of pacritinib application in Europe
seekingalpha.com - February 1 at 9:41 AM
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development UpdateCTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
finance.yahoo.com - February 1 at 9:41 AM
CTI BioPharma: Can It Differentiate Itself From Jakafi In MF Patients?CTI BioPharma: Can It Differentiate Itself From Jakafi In MF Patients?
seekingalpha.com - January 8 at 5:33 PM
CTI Biopharma completes patient enrollment in Phase 2 PAC203 study of pacritinibCTI Biopharma completes patient enrollment in Phase 2 PAC203 study of pacritinib
seekingalpha.com - December 28 at 9:32 AM
CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of PacritinibCTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib
finance.yahoo.com - December 28 at 9:32 AM
CTI Bio sets protocol for late-stage study of pacritinib in myelofibrosisCTI Bio sets protocol for late-stage study of pacritinib in myelofibrosis
seekingalpha.com - December 19 at 9:30 AM
CTI BioPharma (CTIC) Reports Program Update Following Regulatory Feedback from FDA on Pacritinib Development - StreetInsider.comCTI BioPharma (CTIC) Reports Program Update Following Regulatory Feedback from FDA on Pacritinib Development - StreetInsider.com
www.streetinsider.com - December 18 at 4:47 PM
CTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib DevelopmentCTI BioPharma Provides Program Update Following Regulatory Feedback from the U.S. FDA on Pacritinib Development
finance.yahoo.com - December 18 at 4:47 PM
As CTI BioPharma restructures, former CEO James Bianco launches startupAs CTI BioPharma restructures, former CEO James Bianco launches startup
finance.yahoo.com - December 18 at 9:24 AM
CTI BioPharma Announces 50% Reduction In WorkforceCTI BioPharma Announces 50% Reduction In Workforce
www.nasdaq.com - December 13 at 4:55 PM
CTI BioPharma to cut half of workforce in restructuring; shares down 5%CTI BioPharma to cut half of workforce in restructuring; shares down 5%
seekingalpha.com - December 13 at 4:55 PM
CTI BioPharma lays off half of workforce to save cash for lead drug trialCTI BioPharma lays off half of workforce to save cash for lead drug trial
finance.yahoo.com - December 13 at 4:55 PM
CTI BioPharma Announces Restructuring PlanCTI BioPharma Announces Restructuring Plan
finance.yahoo.com - December 13 at 4:55 PM
CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency - PRNewswireCTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency - PRNewswire
www.prnewswire.com - November 28 at 9:39 AM
CTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines AgencyCTI BioPharma Provides Program Update Following Regulatory Feedback on Pacritinib Development from the European Medicines Agency
finance.yahoo.com - November 26 at 4:39 PM
Detailed Research: Economic Perspectives on Jason Industries, XBiotech, Dynatronics, Evolving, CTI BioPharma, and ...Detailed Research: Economic Perspectives on Jason Industries, XBiotech, Dynatronics, Evolving, CTI BioPharma, and ...
globenewswire.com - November 24 at 4:33 PM
European advisory group backs CTI Bios pacritinib for certain myelofibrosis patientsEuropean advisory group backs CTI Bio's pacritinib for certain myelofibrosis patients
seekingalpha.com - November 16 at 4:52 PM
CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q3 2018 Results - Earnings Call TranscriptCTI BioPharma Corp. (CTIC) CEO Adam Craig on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 2 at 9:50 AM
CTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue EstimatesCTI BioPharma (CTIC) Reports Q3 Loss, Tops Revenue Estimates
finance.yahoo.com - November 1 at 4:50 PM
CTI BioPharma: 3Q Earnings SnapshotCTI BioPharma: 3Q Earnings Snapshot
finance.yahoo.com - November 1 at 4:50 PM
CTI BioPharma Q3 Loss WidensCTI BioPharma Q3 Loss Widens
www.nasdaq.com - November 1 at 9:05 AM
CTI BioPharma misses on revenueCTI BioPharma misses on revenue
seekingalpha.com - November 1 at 9:05 AM
CTI BioPharma Reports Third Quarter 2018 Financial ResultsCTI BioPharma Reports Third Quarter 2018 Financial Results
finance.yahoo.com - November 1 at 9:04 AM
CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018
finance.yahoo.com - October 25 at 9:21 AM
Is the Options Market Predicting a Spike in CTI BioPharma (CTIC) Stock?Is the Options Market Predicting a Spike in CTI BioPharma (CTIC) Stock?
finance.yahoo.com - October 1 at 4:24 PM
CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data ReviewCTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review
finance.yahoo.com - October 1 at 9:03 AM
CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3CTI BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference Wednesday, Oct. 3
finance.yahoo.com - September 26 at 9:31 AM
CTI BioPharma co-founder comes to his own defense in yacht repossession lawsuitCTI BioPharma co-founder comes to his own defense in yacht repossession lawsuit
finance.yahoo.com - September 7 at 4:22 PM
CTI BioPharma co-founder and chief scientific officer leaves as stock sits near record lowCTI BioPharma co-founder and chief scientific officer leaves as stock sits near record low
finance.yahoo.com - September 7 at 9:18 AM
Sheriff's deputies can't find CTI BioPharma founder to serve him lawsuit over repossessed yachtSheriff's deputies can't find CTI BioPharma founder to serve him lawsuit over repossessed yacht
finance.yahoo.com - August 29 at 4:19 PM
CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call TranscriptCTI BioPharma Corp. (CTIC) CEO Adam Craig on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 3 at 5:23 PM
CTI BioPharma beats by $0.03, misses on revenueCTI BioPharma beats by $0.03, misses on revenue
seekingalpha.com - August 2 at 4:25 PM
CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue EstimatesCTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates
www.zacks.com - August 2 at 4:25 PM
CTI BioPharma Reports Second Quarter 2018 Financial ResultsCTI BioPharma Reports Second Quarter 2018 Financial Results
finance.yahoo.com - August 2 at 9:56 AM
CTI BioPharma: 2Q Earnings SnapshotCTI BioPharma: 2Q Earnings Snapshot
finance.yahoo.com - August 2 at 9:56 AM
CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018
finance.yahoo.com - July 26 at 4:44 PM
CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDACTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA
finance.yahoo.com - July 19 at 4:15 PM
Today’s Research Reports on Stocks to Watch: CTI BioPharma and Crinetics PharmaceuticalsToday’s Research Reports on Stocks to Watch: CTI BioPharma and Crinetics Pharmaceuticals
finance.yahoo.com - July 19 at 9:02 AM
CTI BioPharma (CTIC) PT Lowered to $7 at Needham & CompanyCTI BioPharma (CTIC) PT Lowered to $7 at Needham & Company
www.streetinsider.com - July 18 at 4:17 PM
CTI BioPharma Has Fallen Almost 39% TodayCTI BioPharma Has Fallen Almost 39% Today
finance.yahoo.com - July 18 at 4:17 PM
Why CTI BioPharma Corp. Crashed TodayWhy CTI BioPharma Corp. Crashed Today
www.fool.com - July 18 at 12:31 PM
CTI BioPharma (CTIC) Reports Pacritinib Program Update Following Type B Meeting with FDACTI BioPharma (CTIC) Reports Pacritinib Program Update Following Type B Meeting with FDA
www.streetinsider.com - July 18 at 8:52 AM
CTI Bio to initiate late-stage study of pacritinib in myelofibrosis in 2019CTI Bio to initiate late-stage study of pacritinib in myelofibrosis in 2019
seekingalpha.com - July 18 at 8:52 AM
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Featured Article: Strike Price

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel